Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH
NCT00564018 · University of Texas Southwestern Medical Center · NA · terminated · last registry update 2019-10-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Presumed loss of clinical equipoise between the agents being investigated” | – | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-28Results posted on the registry: University of Guadalajara, Insulin Degludec + Insulin Glargine (NCT02680457)
- 2020-09-11Results posted on the registry: Northwestern University, NPH Insulin + glargine (NCT03511521)
- 2020-09-11Also stopped (terminated): Northwestern University, NPH Insulin + glargine (NCT03511521)
- 2020-07-08Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04460885)
- 2020-07-07Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT03172494)
- 2020-06-09Also stopped (terminated): Weill Cornell Medical College in Qatar, Insulin Degludec U100 + Insulin Glargine (NCT03349840)
- 2020-05-07Results posted on the registry: Emory University, Glargine U300 + Glargine U100 (NCT03013985)
- 2020-05-01Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03214367)
- 2020-04-09Results posted on the registry: HealthPartners Institute, Insulin glulisine + Placebo (NCT02503501)
- 2020-04-09Also stopped (terminated): HealthPartners Institute, Insulin glulisine + Placebo (NCT02503501)
- 2020-03-27Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03214380)
- 2020-03-19Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT03175120)
- 2020-03-12Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin glargine (NCT03078478)
- 2020-03-12Results posted on the registry: Novo Nordisk A/S, Faster-acting insulin aspart + Insulin aspart (NCT03268005)
- 2020-03-10Also stopped (withdrawn): Providence Health & Services, Switching to NPH insulin + Continuation of insulin glargine (NCT01854723)
- 2020-01-18Results posted on the registry: Universidad de Guanajuato, NPH insulin + Glargine and Lispro insulin (NCT03350984)
- 2020-01-10Phase 3 first posted: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Metformin + Insulin Detemir (NCT04222348)
- 2020-01-07Results posted on the registry: Sanofi, Insulin glargine, 300 units per milliliter (U/mL) + Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) (NCT03260868)
- 2019-12-23Results posted on the registry: Emory University, Sitagliptin + Placebo (NCT02556918)
- 2019-12-12Results posted on the registry: Massachusetts General Hospital, a drug against INSR (NCT01684943)
- 2019-12-06Results posted on the registry: HealthPartners Institute, Insulin glulisine + Saline (NCT02432716)
- 2019-11-27Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin glargine (NCT02501161)
- 2019-10-22Results posted on the registry: University of Texas Southwestern Medical Center, Metformin + Detemir (NCT01966978)
- 2019-08-07Results posted on the registry: Indiana University, liraglutide + insulin detemir (NCT01232946)
- 2019-07-29Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin degludec (NCT02607306)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision